Antitumorigenic potential of STAT3 alternative splicing modulation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 43, 2011, Pages 17779-17784

  Zammarchi, Francesca ^a   De Stanchina, Elisa ^a   Bournazou, Eirini ^a   Supakorndej, Teerawit ^a   Martires, Kathryn ^a   Riedel, Elyn ^a   Corben, Adriana D ^a   Bromberg, Jacqueline F ^a   Cartegni, Luca ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIN C; HISTONE ACETYLTRANSFERASE PCAF; PEROXISOMAL BIOGENESIS FACTOR 1; STAT1BETA PROTEIN; STAT3 PROTEIN; STAT3ALPHA PROTEIN; STAT3BETA PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; EXON; GENETIC MANIPULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR REGRESSION; VALIDATION PROCESS; XENOGRAFT;

ALTERNATIVE SPLICING; ANIMALS; BLOTTING, WESTERN; CELL LINE; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, NUDE; MICROARRAY ANALYSIS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR;

EID: 80055072546     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1108482108     Document Type: Article

References (39)

1. Darnell JE, Jr. (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2:740-749.
2. Haura EB, Turkson J, Jove R (2005) Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2:315-324. (Pubitemid 40903176)
3. Yue P, Turkson J (2009) Targeting STAT3 in cancer: How successful are we? Expert Opin Investig Drugs 18:45-56.
4. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9:798-809.
5. Inghirami G, et al. (2005) New and old functions of STAT3: A pivotal target for individualized treatment of cancer. Cell Cycle 4:1131-1133. (Pubitemid 41365374)
6. Huang Y, et al. (2007) Stat3 isoforms, α and β, demonstrate distinct intracellular dynamics with prolonged nuclear retention of Stat3β mapping to its unique C-terminal end. J Biol Chem 282:34958-34967. (Pubitemid 350232477)
7. Niu G, et al. (2001) Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 61:3276-3280. (Pubitemid 32695012)
8. Gritsko T, et al. (2006) Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12:11-19. (Pubitemid 43166170)
9. Ling X, Arlinghaus RB (2005) Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 65:2532-2536. (Pubitemid 40490046)
10. Zhao W, Jaganathan S, Turkson J (2010) A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J Biol Chem 285:35855-35865.
11. Song H, Wang R, Wang S, Lin J (2005) A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 102:4700-4705. (Pubitemid 40471517)
12. Pedranzini L, et al. (2006) Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 66:9714-9721. (Pubitemid 44623672)
13. Schaefer TS, Sanders LK, Park OK, Nathans D (1997) Functional differences between Stat3α and Stat3β. Mol Cell Biol 17:5307-5316.
14. Dewilde S, Vercelli A, Chiarle R, Poli V (2008) Of &alphas and &betas: Distinct and overlapping functions of STAT3 isoforms. Front Biosci 13:6501-6514.
15. Caldenhoven E, et al. (1996) STAT3β, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J Biol Chem 271:13221-13227. (Pubitemid 26175904)
16. Xu G, Zhang C, Zhang J (2009) Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells. Mol Med Report 2:819-824.
17. Maritano D, et al. (2004) The STAT3 isoforms α and β have unique and specific functions. Nat Immunol 5:401-409. (Pubitemid 38500089)
18. Yoo JY, Huso DL, Nathans D, Desiderio S (2002) Specific ablation of Stat3β distorts the pattern of Stat3-responsive gene expression and impairs recovery from endotoxic shock. Cell 108:331-344. (Pubitemid 34178398)
19. Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: Exonic mutations that affect splicing. Nat Rev Genet 3:285-298. (Pubitemid 34279797)
20. Nilsen TW, Graveley BR (2010) Expansion of the eukaryotic proteome by alternative splicing. Nature 463:457-463.
21. Ward AJ, Cooper TA (2010) The pathobiology of splicing. J Pathol 220:152-163.
22. David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev 24:2343-2364.
23. Bauman J, Jearawiriyapaisarn N, Kole R (2009) Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides 19:1-13.
24. Shao H, Quintero AJ, Tweardy DJ (2001) Identification and characterization of cis elements in the STAT3 gene regulating STAT3 α and STAT3 β messenger RNA splicing. Blood 98:3853-3856.
25. Morcos PA, Li Y, Jiang S (2008) Vivo-Morpholinos: A non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. Biotechniques, 45:613-614 616, 618 passim.
26. Llano M, Morrison J, Poeschla EM (2009) Virological and cellular roles of the transcriptional coactivator LEDGF/p75. Curr Top Microbiol Immunol 339:125-146.
27. Crane DI, Maxwell MA, Paton BC (2005) PEX1 mutations in the Zellweger spectrum of the peroxisome biogenesis disorders. Hum Mutat 26:167-175. (Pubitemid 41254371)
28. Liu ZJ, et al. (1998) A critical role for cyclin C in promotion of the hematopoietic cell cycle by cooperation with c-Myc. Mol Cell Biol 18:3445-3454.
29. Nagy Z, Tora L (2007) Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene 26:5341-5357. (Pubitemid 47255920)
30. Baran-Marszak F, et al. (2004) Differential roles of STAT1α and STAT1β in fludarabine-induced cell cycle arrest and apoptosis in human B cells. Blood 104:2475-2483. (Pubitemid 39331850)
31. Selander KS, et al. (2004) Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res 64:6924-6933. (Pubitemid 39331001)
32. Sasse J, et al. (1997) Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol Cell Biol 17:4677-4686. (Pubitemid 27318143)
33. Takeichi T, et al. (2010) Overexpression of LEDGF/DFS70 induces IL-6 via p38 activation in HaCaT cells, similar to that seen in the psoriatic condition. J Invest Dermatol 130:2760-2767.
34. Rammer P, et al. (2010) BAMLET activates a lysosomal cell death program in cancer cells. Mol Cancer Ther 9:24-32.
35. Shiota M, et al. (2010) P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance. Cancer Sci 101:1797-1806.
36. Hirano G, et al. (2010) Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells. Mol Cancer Res 8:864-872.
37. Moulton HM, et al. (2009) Peptide-morpholino conjugate: A promising therapeutic for Duchenne muscular dystrophy. Ann N Y Acad Sci 1175:55-60.
38. Bauman JA, Li SD, Yang A, Huang L, Kole R (2010) Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res 38:8348-8356.
39. Cirak S, et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 378:595-605.